ID   Y-MESO-8D
AC   CVCL_5189
DR   cancercelllines; CVCL_5189
DR   Cosmic; 2759225
DR   GEO; GSM552524
DR   GEO; GSM850287
DR   IARC_TP53; 24551
DR   Progenetix; CVCL_5189
DR   RCB; RCB5665
DR   Wikidata; Q54995160
RX   PubMed=16630136;
RX   PubMed=17270034;
RX   PubMed=21245096;
RX   PubMed=26011428;
CC   Population: Japanese.
CC   Characteristics: While the primary tumor is biphasic this cell line shows sarcomatoid morphology.
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (PubMed=16630136).
CC   Omics: Array-based CGH.
CC   Omics: Transcriptome analysis by microarray.
CC   Donor information: No history of asbestos exposure (PubMed=16630136).
CC   Misspelling: ACC-MESO-8D; IARC_TP53=24551.
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): RCB=RCB5665
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 8,9
ST   D16S539: 12
ST   D5S818: 11,12
ST   D7S820: 11
ST   TH01: 7,9
ST   TPOX: 11
ST   vWA: 14,16
DI   NCIt; C45663; Pleural sarcomatoid mesothelioma
DI   ORDO; Orphanet_50251; Pleural mesothelioma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_5188 ! Y-MESO-8A
SX   Male
AG   60Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 19-12-24; Version: 21
//
RX   PubMed=16630136; DOI=10.1111/j.1349-7006.2006.00184.x; PMCID=PMC11158456;
RA   Usami N., Fukui T., Kondo M., Taniguchi T., Yokoyama T., Mori S.,
RA   Yokoi K., Horio Y., Shimokata K., Sekido Y., Hida T.;
RT   "Establishment and characterization of four malignant pleural
RT   mesothelioma cell lines from Japanese patients.";
RL   Cancer Sci. 97:387-394(2006).
//
RX   PubMed=17270034; DOI=10.1111/j.1349-7006.2006.00386.x; PMCID=PMC11158069;
RA   Taniguchi T., Karnan S., Fukui T., Yokoyama T., Tagawa H., Yokoi K.,
RA   Ueda Y., Mitsudomi T., Horio Y., Hida T., Yatabe Y., Seto M.,
RA   Sekido Y.;
RT   "Genomic profiling of malignant pleural mesothelioma with array-based
RT   comparative genomic hybridization shows frequent non-random
RT   chromosomal alteration regions including JUN amplification on 1p32.";
RL   Cancer Sci. 98:438-446(2007).
//
RX   PubMed=21245096; DOI=10.1158/0008-5472.CAN-10-2164;
RA   Murakami H., Mizuno T., Taniguchi T., Fujii M., Ishiguro F., Fukui T.,
RA   Akatsuka S., Horio Y., Hida T., Kondo Y., Toyokuni S., Osada H.,
RA   Sekido Y.;
RT   "LATS2 is a tumor suppressor gene of malignant mesothelioma.";
RL   Cancer Res. 71:873-883(2011).
//
RX   PubMed=26011428; DOI=10.1111/cas.12698; PMCID=PMC4556387;
RA   Hakiri S., Osada H., Ishiguro F., Murakami H., Murakami-Tonami Y.,
RA   Yokoi K., Sekido Y.;
RT   "Functional differences between wild-type and mutant-type
RT   BRCA1-associated protein 1 tumor suppressor against malignant
RT   mesothelioma cells.";
RL   Cancer Sci. 106:990-999(2015).
//